Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries
Sang Gune K Yoo,Grace S Chung,Silver K Bahendeka,Abla M Sibai,Albertino Damasceno,Farshad Farzadfar,Peter Rohloff,Corine Houehanou,Bolormaa Norov,Khem B Karki,Mohammadreza Azangou-Khyavy,Maja E Marcus,Krishna K Aryal,Luisa C C Brant,Michaela Theilmann,Renata Cífková,Nuno Lunet,Mongal S Gurung,Joseph Kibachio Mwangi,Joao Martins,Rosa Haghshenas,Lela Sturua,Sebastian Vollmer,Till Bärnighausen,Rifat Atun,Jeremy B Sussman,Kavita Singh,Sahar Saeedi Moghaddam,David Guwatudde,Pascal Geldsetzer,Jennifer Manne-Goehler,Mark D Huffman,Justine I Davies,David Flood
DOI: https://doi.org/10.1001/jama.2023.12905
IF: 11.816
2023-08-22
JAMA
Abstract:Importance: Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD. Objective: To report and evaluate aspirin use for secondary prevention of CVD across low-, middle-, and high-income countries. Design, setting, and participants: Cross-sectional analysis using pooled, individual participant data from nationally representative health surveys conducted between 2013 and 2020 in 51 low-, middle-, and high-income countries. Included surveys contained data on self-reported history of CVD and aspirin use. The sample of participants included nonpregnant adults aged 40 to 69 years. Exposures: Countries' per capita income levels and world region; individuals' socioeconomic demographics. Main outcomes and measures: Self-reported use of aspirin for secondary prevention of CVD. Results: The overall pooled sample included 124 505 individuals. The median age was 52 (IQR, 45-59) years, and 50.5% (95% CI, 49.9%-51.1%) were women. A total of 10 589 individuals had a self-reported history of CVD (8.1% [95% CI, 7.6%-8.6%]). Among individuals with a history of CVD, aspirin use for secondary prevention in the overall pooled sample was 40.3% (95% CI, 37.6%-43.0%). By income group, estimates were 16.6% (95% CI, 12.4%-21.9%) in low-income countries, 24.5% (95% CI, 20.8%-28.6%) in lower-middle-income countries, 51.1% (95% CI, 48.2%-54.0%) in upper-middle-income countries, and 65.0% (95% CI, 59.1%-70.4%) in high-income countries. Conclusion and relevance: Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries. National health policies and health systems must develop, implement, and evaluate strategies to promote aspirin therapy.